Cizzle Biotechnology Ltd.
This article was originally published in Start Up
Executive Summary
Cizzle Biotechnology is focusing on the gene Ciz1 and its variant, found in small-cell lung cancer. The trigger for the start-up's formation was the finding that cells require Ciz1 to grow, and that variant forms could be used for selective targeting of cancer cells, especially small-cell lung cancer. The company's founders have shown that blocking the disrupted form of Ciz1, using a small interfering RNA (siRNA) targeted to the variant, prevented cell proliferation and growth in vitro. The specificity of the Ciz1 variant also gives it potential as a biomarker for early detection of lung cancer.
You may also be interested in...
Start-Up Previews (01/08)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "NOTES Companies Sing an Upbeat Tune," and "Solid Support for Flu Vaccine Development." Plus these Start-Ups Across Health Care: Carigent Therapeutics, Cizzle Biotechnology, Genesis Medical Interventional, and ValveXchange.
Start-Up Previews (01/08)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "NOTES Companies Sing an Upbeat Tune," and "Solid Support for Flu Vaccine Development." Plus these Start-Ups Across Health Care: Carigent Therapeutics, Cizzle Biotechnology, Genesis Medical Interventional, and ValveXchange.
Bristol Rebuilds Oncology Business: Smart Work at FDA Helps
Bristol-Myers Squibb's oncology franchise is at roughly 70% of its level before Taxol went generic and sales began to freefall. But with a couple of recent product launches, expanding indications for others, and a showing that it can naviigate FDA in spaces where competitors have stumbled, it is back on track again.